Not Yet RecruitingPhase 2

QL1706 in Patients With Recurrent and Metastatic Cervical Cancer Resistant to Prior PD-1/PD-L1 Antibody Therapy

50 participantsStarted 2025-10-01

Plain-language summary

To explore the efficacy and safety of administrating QL1706 in patients with recurrent and/or metastatic cervical cancer who had developed resistance to prior PD-1/PD-L1 antibody therapies.

Who can participate

Age range18 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Patients with recurrent/metastatic cervical cancer who previously experienced failure of PD-1 blockade therapy;
✓. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1;
✓. Life expectancy ≥3 months;
✓. At least one measurable lesion per RECIST v1.1:
✓. Adequate organ function within 14 days prior to treatment:
✓. Absolute neutrophil count (ANC) ≥1.0×10⁹/L
✓. Hemoglobin ≥60 g/L
✓. Platelet count ≥50×10⁹/L

Exclusion criteria

✕. Prior treatment with anti-PD-1/CTLA-4 bispecific antibodies;
✕. Active autoimmune disease requiring systemic control with corticosteroids (≥10 mg/day prednisone equivalent) or immunosuppressants within 14 days prior to enrollment;
✕. Clinically significant cardiovascular/cerebrovascular events within 6 months prior to treatment, including:
✕. Acute myocardial infarction
✕. Unstable angina
✕. Cerebrovascular accident
✕. Symptomatic arterial/venous thrombosis or ischemic cardiomyopathy
✕. Clinically significant ventricular arrhythmias (sustained VT, VF, torsades de pointes)

What they're measuring

ORR

Timeframe: 1-year

Trial details

NCT IDNCT07141186

SponsorTianjin Medical University Cancer Institute and Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2027-10-01

Contact for this trial

Chen Li

+86-1551093601 lichen.radonco@tmu.edu.cn

View on ClinicalTrials.gov More Cervical Cancer trials